Annual Report and Accounts for the year ended 30 September 2018

02 Jan 2019

28 December 2018

REDX PHARMA PLC

(“Redx” or “the Company”)

Annual Report and Accounts

 The Company announces that it will today be posting to shareholders the Annual Report and Accounts for the year ended 30 September 2018, together with the notice of the Annual General Meeting.  The Annual General Meeting will be held at 11am on 23 January 2019 at the offices of WG Partners, 85 Gresham Street, London EC2V 7NQ.

 

The Report and Accounts are also available on the Company’s website, www.redxpharma.com.

 

For further information, please contact:

Redx Pharma Plc

T: +44 1625 469 920

Lisa Anson, Chief Executive Officer

Dominic Jackson, Chief Financial Officer

Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)

 T: +44 20 7894 7000

Phil Davies

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert

 

About Redx Pharma Plc 

Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx’s vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/